Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.

View Full Paper
Ask AI
Bookmark
Share

Authors

AIAhmad IbrahimAKAhmad Khalil

Discussion

Loading...

Member takes

Overview

Pilot study shows FLAG-mitoxantrone plus venetoclax improves outcomes in patients with acute myeloblastic leukemia, suggesting effective transition to transplantation.

Key Points

  • FLAG-mitoxantrone combined with venetoclax resulted in a composite complete remission rate of 91%.
  • The long-term outcomes showed a three-year overall survival rate of 68% in newly diagnosed acute myeloblastic leukemia patients.
  • Observational analysis between 2020 and 2025 included patients aged 18 to 60 with newly diagnosed or relapsed acute myeloblastic leukemia.
  • These findings highlight the potential of FLAG-mitoxantrone plus venetoclax as a bridge to allogeneic hematopoietic stem cell transplantation.

Cite This Study

Ibrahim et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9d6https://doi.org/10.1182/blood-2025-5177
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025
  2. 2Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML2025
  3. 3Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia2025 · 1 citations
  4. 4Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations
  5. 5FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China2025 · 1 citations